^
Association details:
| Biomarker: | FGFR2 mutation |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | KIN-3248 (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations
Published date:
01/18/2022
Excerpt:
...KIN-3248 led to dose-dependent tumor growth inhibition and regressions in FGFR inhibitor-resistant, patient-derived gastric cancer and cholangiocarcinoma models harboring secondary FGFR2 kinase domain mutations.
DOI:
10.1200/JCO.2022.40.4_suppl.461
